Int. J. Curr. Res. Med. Sci. (2023). 9(11): 23-28

International Journal of Current Research in Medical Sciences

ISSN: 2454-5716

(A Peer Reviewed, Indexed and Open Access Journal)

www.ijcrims.com

Review Article

Volume 9, Issue 11 -2023

DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.004

Coexisting Conditions: Addressing Diabetes in Sickle Cell Anemia Care

[*]Emmanuel Ifeanyi Obeagu[1], Getrude Uzoma Obeagu[2] and Simeon Ikechukwu Egba[3]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

[3]Department of Biochemistry, Michael Okpara University of Agriculture, Umudike Abia State

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

The coexistence of diabetes mellitus and sickle cell anemia presents a challenging clinical scenario that necessitates a comprehensive and tailored approach to patient care. This review aims to elucidate the complex interplay between diabetes and sickle cell anemia, exploring their shared pathophysiological mechanisms, clinical challenges, and integrated management strategies.Individuals affected by both diabetes and sickle cell anemia face unique health complexities resulting from the convergence of these conditions. The pathophysiological interconnections, encompassing chronic inflammation, oxidative stress, vascular complications, and immune dysfunction, significantly impact disease progression and clinical management. Understanding these intricate interactions is pivotal in formulating effective treatment plans and improving patient outcomes.Clinical management strategies, emphasizing multidisciplinary care, personalized treatment approaches, regular monitoring, and lifestyle modifications, are crucial in navigating the challenges posed by these coexisting conditions. Additionally, addressing glycemic control complexities, pain management, preventive care, and psychosocial support are integral facets of optimizing care for individuals managing both diabetes and sickle cell anemia.This paper consolidates current research findings, clinical perspectives, and best practices to provide insights into the holistic management of individuals affected by diabetes within the context of sickle cell anemia. The integration of these strategies aims to improve patient quality of life, reduce complications, and enhance overall healthcare delivery for this unique patient population.

Keywords: Diabetes Mellitus, Sickle Cell Anemia, Coexisting Conditions, Integrated Care, Management Strategies

Introduction

The intersection of diabetes mellitus and sickle cell anemia presents a complex healthcare landscape, necessitating a holistic and tailored approach to patient care. Diabetes, a metabolic disorder characterized by hyperglycemia, and sickle cell anemia, a hereditary hemoglobinopathy causing red blood cell abnormalities, coexist in a subset of individuals, posing unique challenges to healthcare providers and patients alike. Understanding the intricate interplay between these conditions is imperative for delivering effective and comprehensive care strategies [1-6].The prevalence of sickle cell anemia, particularly in regions with a high incidence of malaria, intersects with the global rise in diabetes prevalence. As individuals with sickle cell anemia now have improved life expectancy due to advancements in healthcare, they face a higher risk of developing diabetes or managing both conditions simultaneously. Managing these coexisting conditions is a complex endeavor, as they can synergistically exacerbate each other's complications, impacting patients' quality of life, morbidity, and mortality [7].

This paper aims to dissect the multifaceted relationship between diabetes and sickle cell anemia, delving into their shared pathophysiological mechanisms, challenges in clinical management, and strategies for integrated care. By synthesizing current knowledge and insights from research, clinical experiences, and best practices, this review seeks to provide a comprehensive guide for healthcare providers navigating the complexities of these coexisting conditions in patient care.

Pathophysiological Interplay between Diabetes and Sickle Cell Anemia

The pathophysiological interplay between diabetes and sickle cell anemia involves intricate mechanisms that impact the progression and severity of both conditions.Both diabetes and sickle cell anemia are associated with chronic inflammation and increased oxidative stress. In diabetes, hyperglycemia leads to the production of reactive oxygen species (ROS) and oxidative stress. In sickle cell anemia, the abnormal sickle hemoglobin causes red blood cell damage, triggering inflammation and oxidative stress. The combination of these factors can exacerbate tissue damage and complications in individuals with both conditions [8-12].Diabetes is notorious for its macrovascular and microvascular complications due to elevated blood glucose levels. Sickle cell anemia, on the other hand, causes vaso-occlusion due to the rigid, sickle-shaped red blood cells that obstruct blood flow. The concurrent presence of diabetes and sickle cell anemia can potentiate vascular complications, leading to an increased risk of strokes, organ damage, and impaired blood circulation [13-16].Both diabetes and sickle cell anemia contribute to endothelial dysfunction. Hyperglycemia in diabetes damages the endothelial lining of blood vessels, impairing their function. In sickle cell anemia, the abnormal red blood cells cause endothelial injury and inflammation. The combination of these factors may heighten the risk of thrombotic events and impair tissue perfusion [17-21].The hemoglobinopathies present in sickle cell anemia can affect glycated hemoglobin (HbA1c) measurements, impacting the accuracy of glucose control assessments in individuals with both conditions. This complicates the management of diabetes in sickle cell anemia patients, necessitating careful interpretation of glycemic markers and adjustments in treatment strategies.Both diabetes and sickle cell anemia can compromise the immune system, leading to an increased susceptibility to infections. Diabetes weakens the immune response, making individuals more prone to infections, while sickle cell anemia can impair the spleen's ability to clear certain infections. The presence of both conditions may further compromise immune function, requiring vigilant monitoring and prompt treatment of infections [22-26].

Clinical Management Strategies

Managing coexisting diabetes and sickle cell anemia requires a comprehensive and individualized approach that considers the unique challenges presented by both conditions [27].Establishing a multidisciplinary care team

involving hematologists, endocrinologists, primary care physicians, nurse educators, dietitians, and other specialists is essential. This collaborative approach ensures comprehensive care, addressing both diabetes and sickle cell anemia complexities.Implementing regular monitoring and screening protocols for both conditions is crucial. This includes monitoring blood glucose levels, HbA1c, complete blood counts, reticulocyte counts, and assessing for any signs of diabetes-related complications and sickle cell crises.Tailoring treatment plans considering the unique needs of each patient is critical. This may involve personalized medication regimens for diabetes management, hydroxyurea therapy for sickle cell anemia, and specific interventions to address complications associated with both conditions [28-30].Balancing glycemic control in individuals with sickle cell anemia can be challenging due to the impact of hemoglobinopathies on HbA1c levels. Continuous monitoring and adjustments in diabetes management are necessary while considering the risk of sickle cell crises.Pain is a significant aspect of sickle cell disease, and it can be exacerbated by diabetes-related neuropathy. Implementing effective pain management strategies, such as non-opioid analgesics, physical therapy, and lifestyle modifications, is crucial in improving the quality of life for patients.Evaluating the potential benefits and risks of hydroxyurea therapy in managing sickle cell anemia and its impact on diabetes control is essential. Hydroxyurea has shown efficacy in reducing sickle cell-related complications and may positively impact some aspects of diabetes control.Emphasizing the importance of a balanced diet, regular exercise, and lifestyle modifications tailored to both conditions. Dietitians can help create meal plans that manage blood glucose levels while addressing the nutritional needs specific to sickle cell anemia.Empowering patients through education on both conditions, medication adherence, recognizing warning signs of complications, and self-care practices. Encouraging self-management skills helps patients actively participate in their care.Ensuring adherence to preventive care measures for diabetes-related complications (e.g., retinopathy, nephropathy) and sickle cell-related complications (e.g., acute chest syndrome, stroke) through regular screenings and interventions.Recognizing the psychosocial impact of managing two chronic conditions and providing access to counseling, support groups, and mental health resources to address the emotional aspects of living with diabetes and sickle cell anemia.A tailored approach that integrates these clinical strategies while considering the specific needs and challenges of each patient is vital in effectively managing coexisting diabetes and sickle cell anemia. Regular reassessment and adjustments in the management plan are essential to optimize outcomes and improve the quality of life for these individuals.

Challenges and Future Directions

Discussion on the challenges faced in managing coexisting diabetes and sickle cell anemia, including limited therapeutic options, potential complications, and the need for tailored care plans. Highlighting the importance of ongoing research and innovative approaches to improve management strategies and outcomes in this population.

Conclusion

In conclusion, the convergence of diabetes mellitus and sickle cell anemia presents a multifaceted clinical scenario, demanding a nuanced and integrated approach to patient care. The intricate interplay between these conditions, characterized by shared pathophysiological mechanisms and the potential exacerbation of complications, underscores the importance of tailored and comprehensive management strategies. Clinical management strategies, including multidisciplinary care, individualized treatment plans, regular monitoring, and lifestyle modifications, play a pivotal role in mitigating the risks and optimizing outcomes for patients grappling with coexisting diabetes and sickle cell anemia. The collaboration among healthcare professionals across various specialties remains crucial in navigating the challenges posed by these dual conditions, ensuring comprehensive and coordinated care delivery.

In essence, a comprehensive, patient-centered approach that recognizes the intricacies of managing both diabetes and sickle cell anemia is essential in providing optimized care, reducing complications, and improving overall well-being for this distinct patient population. Continued research endeavors and clinical innovations will pave the way for further advancements, ultimately leading to enhanced management strategies and improved outcomes in the future.

References

1. Oladiran OO. Exploring How Sickle Cell Disease Impacts the Selection of Romantic Partner and Reproductive Decision Making of Adults with Sickle Cell Disease Living in The United Kingdom (Doctoral dissertation, University of Sheffield).
2. Ifediora AC, Obeagu EI, Akahara IC, Eguzouwa UP. Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. J Bio Innov. 2016;5(1):68-82. links/5ae45fdfaca272ba507eb3c3/PREVALENCE-OF-URINARY-TRACT-INFECTION-IN-DIABETIC-PATIENTS-ATTENDING-UMUAHIA-HEALTH-CARE-FACILITIES.pdf.
3. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Ethanol root extract and fractions of Sphenocentrumjollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2023;2(2): rqad010.
4. Obeagu EI, Obeagu GU. Utilization of Antioxidants in the management of diabetes mellitus patients. J Diabetes Clin Prac. 2018;1(102):2.links/5b6c2dec92851ca65053b74e/Utilization-of-Antioxidants-in-the-Management-of-Diabetes-Mellitus.pdf.
5. Obeagu EI, Okoroiwu IL, Obeagu GU. Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(4):110-7. links/5ae4abee458515760ac07a13/Some-haematological-variables-in-insulin-dependent-diabetes-mellitus-patients-in-Imo-state-Nigeria.pdf.
6. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. Evaluation of some trace elements in streptozocin induced diabetic rats treated with Moringa oleifera leaf powder. WJPMR. 2020;6(12):15-8.links/5fcb587092851c00f8516430/EVALUATION-OF-SOME-TRACE-ELEMENTS-IN-STREPTOZOCIN-INDUCED-DIABETIC-RATS-TREATED-WITH-MORINGA-OLEIFERA-LEAF-POWDER.pdf.
7. Lettre G, Bauer DE. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. The Lancet. 2016;387(10037):2554-64.
8. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022;5(2):113-21.
9. Okafor CJ, Yusuf SA, Mahmoud SA, Salum SS, Vargas SC, Mathew AE, Obeagu EI, Shaib HK, Iddi HA, Moh'd MS, Abdulrahman WS. Effect of Gender and Risk Factors in Complications of Type 2 Diabetic Mellitus among Patients Attending Diabetic Clinic in Mnazi Mmoja Hospital, Zanzibar. Journal of Pharmaceutical Research International. 2021;33(29B):67-78.
10. Galano ES, Yusuf SA, Ogbonnia SO, Ogundahunsi OA, Obeagu EI, Chukwuani U, Okafor CJ, Obianagha NF. Effect of Extracts of Kigelia Africana Fruit and Sorghum Bicolor Stalk on the Biochemical Parameters of Alloxan-Induced Diabetic Rats. Journal of Pharmaceutical Research International. 2021;33(25B):86-97.
11. Kama SC, Obeagu EI, Alo MN, Ochei KC, Ezugwu UM, Odo M, Ikpeme M, Ukeekwe CO, Amaeze AA. Incidence of Urinary Tract Infection among Diabetic Patients in Abakaliki Metropolis. Journal of

Pharmaceutical Research International. 2020;32(28):117-21.
12. Nwakulite A, Obeagu EI, Eze R, Vincent CC, Chukwurah EF, Okafor CJ, Ibekwe AM, Adike CN, Chukwuani U, Ifionu BI. Evaluation of Catalase and Manganese in Type 2 Diabetic Patients in University of Port Harcourt Teaching Hospital. Journal of Pharmaceutical Research International. 2021:40-5.
13. Nwakulite A, Obeagu EI, Nwanjo HU, Nwosu DC, Nnatuanya IN, Vincent CC, Amaechi CO, Ochiabu O, Barbara MT, Ibekwe AM, Okafor CJ. Studies on Pancreatic Gene Expression in Diabetic Rats Treated with Moringa oleifera Leaf. Journal of Pharmaceutical Research International. 2021;33(28A):78-86.
14. Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia. Asian Journal of Dental and Health Sciences. 2023;3(2):32-6.http://ajdhs.com/index.php/journal/article/view/43.
15. Adu ME, Chukwuani U, Ezeoru V, Okafor CJ, Amaechi CO, Vincent CC, Obeagu GU, Eze R, Nnatuanya IN, Nwosu DC, Nwanjo HU. Studies on molecular docking of moringa oleifera leaf phytochemical constituents on alpha glucosidase, alpha amylase and dipeptidyl peptidase. Journal of Pharmaceutical Research International. 2021;33(28A):239-45.
16. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Obeagu EI. Plasma Level of Macromolecules and Mathematical Calculation of Potential Energy in Type 2 Diabetic Individuals at NAUTH, Nnewi, Nigeria. Journal of Pharmaceutical Research International. 2021;33(47B):242-8.
17. Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U. Estimation of Serum Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. Journal of Pharmaceutical Research International. 2021;33(30B):200-6.
18. Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertairy hospital in Enugu, south-east Nigeria. ACADEMIC JOURNAL. 2023.
19. Okoroiwu IL, Obeagu EI, Obeagu GU, Chikezie CC, Ezema GO. The prevalence of selected autoimmune diseases. Int. J. Adv. Multidiscip. Res. 2016;3(3):9-14.
20. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF ENZYME ANTIOXIDANTS IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. European Journal of Biomedical. 2020;7(11):285-8.
21. Nwosu DC, Nwanjo HU, Opara AU, Ofor IB, Obeagu EI, Ugwu GU, Ojiegbe GC, Nnorom RM, Nwokike GI, Okpara KE, Ochei KC. EVALUATION OF C-REACTIVE PROTEIN, SELENIUM AND GLYCOSYLATED HAEMOGLOBIN LEVELS IN DIABETIC PATIENTS ATTENDING METABOLIC CLINIC IN THE FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. **World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):141-152.**https://www.academia.edu/download/38320132/NWOSU_EMMA_9.pdf.
22. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF KIDNEY INJURY MOLECULE-1, CYSTATIN C, AND SERUM ELECTROLYTES IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. Education. 2005.
23. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and gas chromatography-mass spectrometry (GC-MS) analysis of ethanol root extract and fractions of Sphenocentrumjollyanum. RPS Pharmacy and Pharmacology Reports. 2023;2(2): rqad007.

24. Obeagu EI, Scott GY, Amekpor F, Ugwu OP, Alum EU. Covid-19 Infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023;11(1):25-30.
25. Ugwu OP, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AO, Amusa MO, Adepoju AO. Effect of Ethanol leaf extract of Chromolaena odorata on lipid profile of streptozotocin induced diabetic wistar albino rats. IAA Journal of Biological Sciences. 2023;10(1):109-17.
26. Ifeanyi OE. Gestational Diabetes: Haematological Perspective. South Asian Research Journal of Applied Medical Sciences, 1 (2):41-42. DOI: 10.36346/SARJAMS.2019.v01i02.003 https://sarpublication.com/media/articles/SARJAMS_12_41-42.pdf.
27. Houwing ME, De Pagter PJ, Van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW, Schols EM, Philipsen JN, Tamminga RY, van Draat KF, Nur E. Sickle cell disease: clinical presentation and management of a global health challenge. Blood reviews. 2019; 37:100580.
28. Ogbu IS, Odeh EJ, Ifeanyichukwu OE, Ogbu C, Ude UA, Obeagu EI. Prevalence of prediabetes among first degree relatives of type 2 diabetes individuals in Abakaliki, Ebonyi State Nigeria. Academic Journal of Health Sciences: MedicinaBalear. 2023;38(2):85-8.https://dialnet.unirioja.es/servlet/articulo?codigo=8845439.
29. Ifeanyi OE. An update on Diabetes Mellitus. Int. J. Curr. Res. Med. Sci. 2018;4(6):71-81.DOI: 10.22192/ijcrms.2018.04.06.012 links/5b3b97a04585150d23f63e76/An-update-on-Diabetes-Mellitus.pdf.
30. Nwosu DC, Nwanjo HU, Obeagu EI, Ugwu GU, Ofor IB, Okeke A, Ochei KC, Kanu SN, Okpara KE. EVALUATION OF LIPOPROTEIN A AND LIPID TETRAD INDEX PATTERN IN DIABETIC PATIENTS ATTENDING METABOLIC CLINIC IN THE FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):126-140 links/5a4fd1a00f7e9bbc10526b54/EVALUATION-OF-LIPOPROTEIN-A-AND-LIPID-TETRAD-INDEX-PATTERN-IN-DIABETIC-PATIENTS-ATTENDING-METABOLIC-CLINIC-IN-THE-FEDERAL-MEDICAL-CENTRE-OWERRI-IMO-STATE.pdf.

Access this Article in Online	
	Website: www.ijcrims.com
Quick Response Code	Subject: Medical Sciences

How to cite this article:
Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu and Simeon Ikechukwu Egba. (2023). Coexisting Conditions: Addressing Diabetes in Sickle Cell Anemia Care. Int. J. Curr. Res. Med. Sci. 9(11): 23-28. DOI: http://dx.doi.org/10.22192/ijcrms.2023.09.11.004